anticoagulant, curative dose - versus control - for COVID-19 pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

deaths 1.05 [0.82, 1.35]< 10%1 study (1/-)35.9 %some concernnot evaluable moderatecrucial-
clinical improvement 0.87 [0.70, 1.08]> 10%1 study (1/-)10.4 %some concernnot evaluable moderateimportant-
Major thrombotic events or death 0.95 [0.74, 1.22]< 10%1 study (1/-)66.0 %some concernnot evaluable moderatenon important-

safety endpoints 00

Major bleeding 1.29 [0.60, 2.79]< 10%1 study (1/-)25.7 %some concernnot evaluable moderatenon important-

LoD: level of demonstration ( demonstrated, suggested, inconclusive, safety concerns);
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.